Table 3.
Baseline characteristics for all included patients (N=26,675). Values are n (%) or median (IQR)
| Variables | All patients (N=26,675) | Blood eosinophil and ICS group | |||
|---|---|---|---|---|---|
| Higher blood eosinophils & ICS (N=11,461) | Higher blood eosinophils & no ICS (N=6,716) | Lower blood eosinophils & ICS (N=5,140) | Lower blood eosinophils & no ICS (N=3,358) | ||
| Female gender | 12,379 (46.4) | 5,206 (45.4) | 2,574 (38.3) | 2,920 (56.8) | 1,679 (50.0) |
| Age (years) | 69 (62–89) | 69 (62–76) | 69 (62–76) | 70 (62–77) | 69 (62–77) |
| Current smoking status | 12,825 (48.1) | 5,195 (45.3) | 3,564 (53.1) | 2,361 (45.9) | 1,705 (50.8) |
| History of MI | 2,415 (9.1) | 1,105 (9.6) | 687 (10.2) | 380 (7.4) | 243 (7.2) |
| History of stroke | 401 (1.5) | 165 (1.4) | 104 (1.6) | 76 (1.5) | 56 (1.7) |
| History of heart failure | 1,802 (6.8) | 786 (6.9) | 428 (6.4) | 380 (7.4) | 208 (6.2) |
| History of lung cancer | 171 (0.6) | 56 (0.5) | 42 (0.6) | 43 (0.8) | 30 (0.9) |
| History of bronchiectasis | 616 (2.3) | 317 (2.8) | 91 (1.4) | 154 (3.0) | 54 (1.6) |
| History of GORD | 1,761 (6.6) | 780 (6.8) | 371 (5.5) | 378 (7.4) | 232 (6.9) |
| History of anxiety | 2,133 (8.0) | 919 (8.0) | 453 (6.8) | 466 (9.1) | 295 (8.8) |
| History of depression | 2,343 (8.8) | 1,028 (9.0) | 545 (8.1) | 488 (9.5) | 282 (8.4) |
| History of asthma | 9,623 (36.1) | 5,839 (51.0) | 574 (8.6) | 2,540 (49.4) | 279 (8.3) |
| BMI (kg/m2) (N=25,528) | 26.8 (23.3–30.8) | 27.3 (23.7–31.3) | 26.9 (23.4–30.8) | 26.5 (23.0–30.7) | 25.7 (22.3–29.7) |
| White blood cell count (cells/µL) | 7.6 (6.4–9.1) | 7.9 (6.6–9.3) | 7.8 (6.6–9.2) | 7.2 (6.0–8.7) | 7.1 (5.9–8.5) |
| Neutrophil count (cells/µL) (N=26,585) | 4.5 (3.6–5.7) | 4.7 (3.7–5.8) | 4.5 (3.6–5.6) | 4.5 (3.5–5.8) | 4.3 (3.4–5.5) |
| Airflow obstruction (N=26,518) Mild (≥80% FEV1 predicted) Moderate (50–80% FEV1 predicted) Severe (30–50% FEV1 predicted) Very severe (≤30% FEV1 predicted) |
5,550 (20.9) 13,834 (52.2) 5,988 (22.6) 1,146 (4.3) |
2,185 (19.2) 5,640 (49.5) 2,935 (25.8) 633 (5.6) |
1,556 (23.3) 3,879 (58.1) 1,092 (16.3) 154 (2.3) |
957 (18.8) 2,469 (48.4) 1,407 (27.6) 270 (5.3) |
852 (25.5) 1,846 (55.3) 554 (16.6) 89 (2.7) |
| AECOPD frequency 0 1 ≥2 |
11,105 (41.6) 6,593 (24.7) 8,977 (33.7) |
4,000 (34.9) 2,788 (24.3) 4,673 (40.8) |
3,501 (52.1) 1,688 (25.1) 1,527 (22.7) |
1,828 (35.6) 1,212 (23.6) 2,100 (40.9) |
1,776 (52.9) 905 (27.0) 677 (20.2) |
| MRC dyspnoea score (N=18,090) 1 2 3 4 5 |
3,749 (20.7) 7,457 (41.2) 4,435 (24.5) 2,066 (11.4) 383 (2.1) |
1,313 (17.6) 2,911 (39.0) 2,030 (27.2) 998 (13.4) 215 (2.9) |
1,287 (26.2) 2,177 (44.3) 986 (20.1) 396 (8.1) 66 (1.3) |
531 (15.8) 1,315 (39.2) 945 (28.2) 493 (14.7) 68 (2.0) |
618 (26.2) 1,054 (44.7) 474 (20.1) 179 (7.6) 34 (1.4) |
Abbreviations: AECOPD, exacerbations of COPD; BMI, body mass index; ICS, inhaled corticosteroids; MI, myocardial infarction; GORD, gastro-oesophageal reflux disease.